WAY-262611 (Synonyms: BML-WN110, Dickkopf-1 Inhibitor, Dkk1 Inhibitor) |
Catalog No.GC15753 |
WAY-262611은 wingless β-Catenin agonist로 TCF-Luciferase assay에서 EC50이 0.63μM로 골형성속도를 증가시킨다. WAY-262611은 또한 Dkk1 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1123231-07-1
Sample solution is provided at 25 µL, 10mM.
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay.
WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility[1].
WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt β-catenin pathway and most likely through inhibition of Dkk-1[1].
References:
[1]. Pelletier JC, et al. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-catenin agonist that increases bone formation rate. J Med Chem. 2009 Nov 26;52(22):6962-5.
Average Rating: 5
(Based on Reviews and 17 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *